Clinical Trial

to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
Trial Details
NCT Number NCT07142798
Lead Sponsor Kaohsiung Medical University
Collaborators: An-Nan Hospital, China Medical University
Conditions HELICOBACTER PYLORI INFECTIONS
Enrollment 200 participants
Start Date 2024-09-26
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-27